On October 13, 2025, ASP Isotopes Inc. announced a new supply contract with a U.S. customer for enriched silicon‑28, the company’s largest silicon‑28 contract to date. Deliveries are scheduled for the first quarter of 2026.
The silicon‑28 contract underscores the growing demand for high‑purity silicon‑28 in quantum computing and advanced semiconductor manufacturing. By securing this order, ASP Isotopes positions itself as a reliable supplier for the next‑generation quantum processors and high‑precision electronics.
In addition, ASP Isotopes announced the acquisition of an independent radiopharmacy in Florida, expanding the operations of its subsidiary PET Labs. The acquisition is expected to be accretive to 2026 revenues, EBITDA, and EPS, and will allow PET Labs to begin offering PET services in the United States from 2027.
The company also granted a restricted stock award to a new employee of ASP Isotopes, covering 30,000 shares vesting over four years. This move supports the company’s strategy to attract and retain talent while reinforcing its commitment to expanding its isotope and radiopharmacy businesses.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.